DTC programs aim to enhance patient access by offering lower prices, but require navigating complex regulatory and licensing ...

In today’s Pharmaceutical Executive Daily, we cover Bristol Myers Squibb’s $1.5 billion acquisition of Orbital Therapeutics, ...

Ypsomed invests $250 million in a new U.S. manufacturing facility, enhancing local supply and creating jobs in Holly Springs, ...

Another major pharmaceutical company is striking a deal with President Trump.

Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its ...

How will pharma companies react to the administration's efforts? Dr. William Soliman: We’ve seen Pfizer doing a deal with Trump, and I think other companies will follow. If they can come to a ...

Shana Tetrault, PhD, Director of Product Marketing at Quanterix, outlined strategies for integrating blood-based biomarkers into routine clinical care pathways, ensuring minimal disruption for ...

Regeneron's Libtayo gains FDA approval as the first immunotherapy for high-risk cutaneous squamous cell carcinoma, enhancing ...

Chris Spivey, Director of Industrial Relations and Strategic Partnerships for Industry Sciences One at MJH Life Sciences, and Raymond J. Deshaies, PhD, Executive Officer of Molecular Biology at the ...

Legal challenges to the MFN order may focus on constitutional issues and the statutory authority of the HHS Secretary, ...

Novo Nordisk acquires Akero Therapeutics to enhance its portfolio with efruxifermin, a promising treatment for metabolic ...

In America, 80% of people on drugs are on generics. We talk a lot about pharma pricing, but the majority of people who are on multiple medications are on generics. For those drugs, you’re not going to ...